Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT03340493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT03340493
-
- Other papers using this trial's data
- Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study
- Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT03340493. Randomized; single masking; primary purpose treatment. Start 2017-12-06 (actual); primary completion 2019-07-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Lead sponsor
- Neuroscience Trials Australia
- Collaborator
- The Florey Institute of Neuroscience and Mental Health
Record details
- Record id
cardio:ct-nct03340493- Content hash
a3cfc0491cf1dce28a1242ca226f23f4a7dcd26ddf3ca13cfb3b24ca68e7f9d1